Medpace (NASDAQ:MEDP) reports Q3 2026 in line with expectations

Medpace reported Q3 2026 revenue of $716M, beating estimates by $2.3M, with EPS of $4.84, a 9.3% beat. Adjusted EBITDA was $172.1M, an 8% beat. The company reconfirmed its full-year revenue guidance of $2.85B and raised EPS guidance to $18.15, a 3.2% beat. Operating margin improved to 23.1%, while free cash flow margin declined to 27.4%.

Original reporting
Published Oct 21, 2026, 8:28 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 21, 2026, 8:35 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Medpace (NASDAQ:MEDP) reports Q3 2026 in line with expectations — source image
Decision brief

The 30-second read

$MEDPBullishMed
01

Why it matters

The combination of in-line revenue, GAAP EPS beat, adjusted EBITDA beat, and reconfirmed full-year guidance suggests a generally constructive earnings outcome, with the main caution flag being weaker free cash flow margin versus the prior-year quarter.

02

Market read

Traders can reassess near-term expectations for Medpace’s earnings power and guidance credibility based on the reported beats and unchanged full-year targets.

03

What to watch

The article notes FCF margin decline (27.4% vs 35.7% prior-year quarter), which may signal working-capital or timing effects not captured by EPS/EBITDA.

Relevance 8/10Novelty 8/10Timing: after-hours earnings/guidance update (published 2026-10-21 20:28:45 UTC)

Background

The piece summarizes Medpace’s Q3 2026 performance versus analyst estimates and reiterates full-year guidance midpoints.

Company-level read

Ticker impact

$MEDPBullishMedium confidence
Context

Medpace reported Q3 2026 revenue of $716M and GAAP EPS $4.84, and reconfirmed full-year revenue guidance at $2.85B midpoint.

Expected impact

Likely upward pressure as the market digests in-line revenue but beats in GAAP EPS and EBITDA, plus unchanged full-year guidance.

Evidence & confidence

The article provides multiple beat metrics (GAAP EPS, adjusted EBITDA, and full-year GAAP EPS and EBITDA guidance) while revenue is only in line; reconfirmed guidance reduces downside risk.

Market effects

Positive read-through for clinical research outsourcing demand expectations, though the article is single-company focused.

Limited broader regional impact; primarily affects US small/mid-cap healthcare services sentiment.

Low global spillover beyond investor sentiment for CRO peers.

Counterpoint

Free cash flow margin fell sharply year over year, which could temper enthusiasm if investors prioritize cash conversion over earnings.

Key entities

  • Medpace

    NASDAQ-listed CRO reporting Q3 2026 results and reconfirmed full-year guidance.

Related articles

$MEDPMedAI 8/10

MEDP Q3 deep dive: bookings strength drives growth, margin expansion continues

MEDP reported Q3 revenue of $716M, beating estimates, with EPS of $4.84 and adjusted EBITDA of $172.1M. The company reconfirmed full-year revenue guidance of $2.85B and raised EPS guidance to $18.15. Growth was driven by strong bookings in oncology research and margin expansion from a favorable project mix. Management highlighted stable competition, low turnover, and sustained bookings momentum, but noted project cancellations as a watchpoint.

$MEDPMedAI 8/10

Medpace 3Q 2026: Revenue $716M, EPS $4.84— 10-Q Summary

Medpace Holdings reported Q3 2026 revenue of $716M, up 8.5% YoY, with net income rising 23.7% to $137.46M and EPS increasing 25.4% to $4.84. Growth was driven by Metabolic, Oncology, and CNS services. Nine-month revenue grew 16.9%, net awards reached $873.4M, and backlog increased 5.6% YoY to $3.17B. The company plans organic growth and selective acquisitions.

$MEDPHighAI 8/10

Medpace (MEDP) Q3 2026 Earnings Call Transcript

Medpace (MEDP) reported Q3 2026 revenue of $716M, up 8.5% YoY, with EBITDA of $172.1M (up 16%) and net income of $137.5M (up 23.7%). Guidance raised: revenue $2.835B-$2.855B (12-12.8% growth), EBITDA $638M-$652M (14.4-16.9% growth), EPS $17.97-$18.32. Board approved $1B share repurchase program. Net new business awards up 10.6% QoQ.

$MEDPMed

Medpace Q3 Earnings Call Highlights

Medpace reported a 10.6% year-over-year increase in net new business awards to $873.4 million in Q3, with a total 12-month backlog of $3.02 billion. Ending backlog was $3.2 billion, up 5.6% year-over-year. The company expects $1.99 billion of backlog to convert into revenue over the next year. Management noted shifts in therapeutic mix and strong pending opportunities. Medpace plans to provide 2027 guidance in February, with fourth-quarter awards and cancellations influencing the outlook.

$MEDPHighAI 8/10

Medpace Q3 2026 slides: record awards fuel profit beat, guidance raised

Medpace Holdings (NASDAQ:MEDP) reported Q3 2026 revenue of $716.0M, up 8.5% YoY, and adjusted earnings of $4.84 per share, exceeding estimates. Net income rose 23.7% to $137.5M, with EBITDA margin widening to 24.0%. The company raised its full-year guidance, citing record new business awards and strong profitability trends. Shares traded near $659.37, close to their 52-week high.